Repatha Liver Function Impact: What the Clinical Evidence Actually Shows

Does Repatha affect liver function?

The label addresses the liver in two ways: no dose adjustment for mild to moderate hepatic impairment, and lower evolocumab exposure in that group [1]. Its safety sections are not about the liver; the only Warning and Precaution is hypersensitivity, including angioedema, and the only contraindication is a history of a serious hypersensitivity reaction to evolocumab or an excipient [1].

Evolocumab is a human monoclonal IgG2 antibody that binds PCSK9 [1]. PCSK9 normally binds the LDL receptor on hepatocytes and promotes its degradation, so blocking that binding leaves more LDL receptors on the liver cell surface to clear LDL from the blood [1].

What the label says about hepatic impairment

In mild to moderate hepatic impairment, evolocumab Cmax was 20 to 30% lower and AUC 40 to 50% lower than in people with normal hepatic function [1]. Dosing is otherwise standard: 140 mg every 2 weeks or 420 mg once monthly, both subcutaneous [1]. The label describes elimination by target binding and proteolysis, with an effective half-life of 11 to 17 days [1].

What the outcome trials report

FOURIER randomized 27,564 adults with established atherosclerotic cardiovascular disease on statin therapy to evolocumab or placebo, with median follow-up of 2.2 years; adverse events did not differ significantly between groups except injection-site reactions, 2.1% versus 1.6% [2]. VESALIUS-CV randomized 12,257 people with atherosclerosis or diabetes and no previous myocardial infarction or stroke, median follow-up 4.6 years, and reported no evidence of a between-group difference in safety events [3].

Repatha with a statin

Every FOURIER participant was on statin therapy and 69% were on a high-intensity statin [2]. The label reports about 20% lower evolocumab Cmax and AUC in adults on a high-intensity statin, a difference it calls not clinically meaningful, and it contains no drug interactions section [1].